<DOC>
	<DOC>NCT02896855</DOC>
	<brief_summary>This Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial in China will evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel compared with placebo + trastuzumab + docetaxel in participants with previously untreated HER2-positive MBC.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease that is suitable for chemotherapy HER2positive MBC Left ventricular ejection fraction (LVEF) greater than or equal to (&gt;=) 55 percent (%) at baseline (within 42 days of randomization) Eastern Cooperative Oncology Group Performance Status of 0 or 1 Women of childbearing potential and men should agree to use an effective form of contraception and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment (trastuzumab and/or pertuzumab) History of anticancer therapy for MBC (with the exception of one prior hormonal regimen for MBC) History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the neoadjuvant or adjuvant setting History of systemic breast cancer treatment in the neoadjuvant or adjuvant setting with a diseasefree interval from completion of the systemic treatment (excluding hormonal therapy) to metastatic diagnosis of less than (&lt;) 12 months History of persistent Grade &gt;= 2 hematologic toxicity resulting from previous adjuvant therapy Grade &gt;= 3 peripheral neuropathy at randomization History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or nonmelanoma skin carcinoma that has been previously treated with curative intent Current clinical or radiographic evidence of central nervous system (CNS) metastases History of exposure to cumulative doses of anthracyclines Current uncontrolled hypertension or unstable angina History of congestive heart failure (CHF) of any New York Heart Association (NYHA) classification, or serious cardiac arrhythmia requiring treatment History of myocardial infarction within 6 months of randomization History of LVEF decrease to &lt; 50% during or after prior trastuzumab neoadjuvant or adjuvant therapy Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy Inadequate organ function within 28 days prior to randomization Current severe, uncontrolled systemic disease Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment Pregnant or lactating women History of receiving any investigational treatment within 28 days of randomization Current known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or active hepatitis B virus (HBV) Receipt of intravenous (IV) antibiotics for infection within 14 days of randomization Current chronic daily treatment with corticosteroids (excluding inhaled steroids) Known hypersensitivity to any of the protocolspecified study treatments Concurrent participation in an interventional or noninterventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>